Milberg Peter, Tegelkamp Regina, Osada Nani, Schimpf Rainer, Wolpert Christian, Breithardt Günter, Borggrefe Martin, Eckardt Lars
Department of Cardiology and Angiology, Hospital of the Westfälische Wilhelms-University, Münster, Germany.
J Cardiovasc Electrophysiol. 2007 Jun;18(6):658-64. doi: 10.1111/j.1540-8167.2007.00813.x.
Short QT syndrome (SQTS) is a newly described ion channelopathy, characterized by a short QT interval resulting from an accelerated cardiac repolarization, associated with syncope, atrial fibrillation, and sudden cardiac death due to ventricular fibrillation. As therapeutic options in SQTS are still controversial, we examined antiarrhythmic mechanisms in an experimental model of SQTS.
Pinacidil, an I(K-ATP) channel opener, was administered in increasing concentrations (50-100 microM) in 48 Langendorff-perfused rabbit hearts and led to a significant reduction of action potential duration and QT interval, thereby mimicking SQTS. Eight simultaneously recorded monophasic action potentials demonstrated an increase in dispersion of repolarization, especially between the left and the right ventricle. During programmed ventricular stimulation with up to two extrastimuli, pinacidil significantly increased the inducibility of ventricular fibrillation (1 heart under baseline conditions, 29 hearts during pinacidil administration; P = 0.0001). Additional treatment with the I(Kr) blocker sotalol (100 microM) and the class I antiarrhythmic drugs flecainide (2 microM) and quinidine (0.5 microM) randomly assigned to three groups of 16 hearts led to prolongation of repolarization as well as refractory period. Sotalol or flecainide did not reduce the rate of inducibility of ventricular fibrillation significantly (P = 0.63; P = 0.219). However, quinidine reduced the inducibility of ventricular fibrillation by 73% (P = 0.008). The antiarrhythmic potential of quinidine was associated with a significantly greater prolongation of MAP duration, refractoriness, and postrepolarization refractoriness (PRR) as compared with sotalol and flecainide. Moreover, quinidine, in contrast to sotalol and flecainide, reduced dispersion of repolarization.
Pinacidil mimics SQTS via increasing potassium outward currents, thereby facilitating inducibility of ventricular fibrillation. Quinidine demonstrates superior antiarrhythmic properties in the treatment of ventricular fibrillation in this model as compared with sotalol and flecainide because of its effects on refractoriness, PRR, and by reducing dispersion of repolarization.
短QT综合征(SQTS)是一种新描述的离子通道病,其特征是由于心脏复极加速导致QT间期缩短,与晕厥、心房颤动以及室颤所致的心源性猝死相关。由于SQTS的治疗选择仍存在争议,我们在SQTS实验模型中研究了抗心律失常机制。
在48个Langendorff灌注兔心脏中,以递增浓度(50 - 100微摩尔)给予I(K-ATP)通道开放剂吡那地尔,导致动作电位时程和QT间期显著缩短,从而模拟了SQTS。同时记录的8个单相动作电位显示复极离散度增加,尤其是在左心室和右心室之间。在进行最多两次额外刺激的程序性心室刺激期间,吡那地尔显著增加了室颤的诱发性(基线条件下1个心脏,吡那地尔给药期间29个心脏;P = 0.0001)。将I(Kr)阻滞剂索他洛尔(100微摩尔)以及I类抗心律失常药物氟卡尼(2微摩尔)和奎尼丁(0.5微摩尔)随机分配到三组,每组16个心脏进行额外治疗,结果导致复极以及不应期延长。索他洛尔或氟卡尼并未显著降低室颤的诱发性(P = 0.63;P = 0.219)。然而,奎尼丁使室颤的诱发性降低了73%(P = 0.008)。与索他洛尔和氟卡尼相比,奎尼丁的抗心律失常潜力与动作电位时程、不应期以及复极后不应期(PRR)的显著延长有关。此外,与索他洛尔和氟卡尼不同,奎尼丁降低了复极离散度。
吡那地尔通过增加钾外向电流模拟SQTS,从而促进室颤的诱发性。在该模型中,与索他洛尔和氟卡尼相比,奎尼丁在治疗室颤方面表现出更优的抗心律失常特性,这是由于其对不应期、PRR的影响以及降低了复极离散度。